US EditionNext-Gen Shigella Vaccine Enters Final Trials Under Bharat Biotech Leadership
Summary by thenewsfacts.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Next-Gen Shigella Vaccine Enters Final Trials Under Bharat Biotech Leadership
June 12, 2025: Bharat Biotech International Limited (BBIL) has announced a strategic partnership with global pharmaceutical giant GSK for the continued development and potential deployment of altSonflex1-2-3, a promising Shigella vaccine candidate targeting Shigellosis — a severe diarrhoeal disease primarily affecting children under five in low- and middle-income countries. The collaboration represents a major milestone in global public health, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
